021-51111890
购物车（）
sales@molnova.cn
Chiglitazar
CAS No. 1959588-75-0
Chiglitazar ( CS-038 | CS038 )
产品货号. M13073 CAS No. 1959588-75-0
Chiglitazar (CS-038, CS038) 是一种有效的 PPARα/γ 双重激动剂，对 PPARα、PPARγ 和 PPARδ 的 EC50 分别为 1.2、0.08、1.7 uM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Chiglitazar
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Chiglitazar (CS-038, CS038) 是一种有效的 PPARα/γ 双重激动剂，对 PPARα、PPARγ 和 PPARδ 的 EC50 分别为 1.2、0.08、1.7 uM。
-
产品描述Chiglitazar (CS-038, CS038) is a potent, dual PPARα/γ dual agonist with EC50 of 1.2, 0.08, 1.7 uM for PPARα, PPARγ and PPARδ, respectively; inhibited alanine gluconeogenesis, lowered the hepatic glycogen level in MSG obese rats. Like rosiglitazone, chiglitazar promoted the differentiation of adipocytes and decreased the maximal diameter of adipocytes; Chiglitazar reduced plasma triglyceride, total cholesterol (TCHO), nonesterified fatty acids (NEFA) and low density lipoprotein-cholesterol levels; lowered hepatic triglyceride and TCHO contents; decreased muscular NEFA level. Unlike rosiglitazone, chiglitazar showed significant increase of mRNA expression of PPARα, CPT1, BIFEZ, ACO and CYP4A10 in the liver of MSG obese rats.Diabetes Phase 3 Clinical.
-
体外实验——
-
体内实验——
-
同义词CS-038 | CS038
-
通路Metabolic Enzyme/Protease
-
靶点PPAR
-
受体PPAR
-
研究领域Metabolic Disease
-
适应症Diabetes
化学信息
-
CAS Number1959588-75-0
-
分子量594.618
-
分子式C36H28FN2NaO4
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)CC(C(=O)[O-])NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F.[Na+]
-
化学全称3-(4-(2-(9H-carbazol-9-yl)ethoxy)phenyl)-2-((2-(4-fluorobenzoyl)phenyl)amino)propanoic acid sodium salt
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Li PP, et al. Br J Pharmacol. 2006 Jul;148(5):610-8.
2. He BK, et al. PPAR Res. 2012;2012:546548.
3. Pan DS, et al. PPAR Res. 2017;2017:4313561.
